A Phase I, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given With Prophylactic G-CSF in Subjects With Solid Tumors.

Trial Profile

A Phase I, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given With Prophylactic G-CSF in Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2011

At a glance

  • Drugs Filgrastim; PR 104
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 31 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 01 Mar 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Mar 2011 Planned end date changed from 1 Aug 2008 to 1 Sep 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top